Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sensus Healthcare (SRTS) Research & Development (2016 - 2025)

Sensus Healthcare has reported Research & Development over the past 10 years, most recently at $1.9 million for Q4 2025.

  • Quarterly results put Research & Development at $1.9 million for Q4 2025, up 20.56% from a year ago — trailing twelve months through Dec 2025 was $7.8 million (up 84.49% YoY), and the annual figure for FY2025 was $7.8 million, up 84.49%.
  • Research & Development for Q4 2025 was $1.9 million at Sensus Healthcare, up from $1.8 million in the prior quarter.
  • Over the last five years, Research & Development for SRTS hit a ceiling of $2.6 million in Q1 2025 and a floor of $661000.0 in Q1 2021.
  • Median Research & Development over the past 5 years was $925500.0 (2021), compared with a mean of $1.1 million.
  • Biggest five-year swings in Research & Development: plummeted 46.04% in 2021 and later surged 181.43% in 2025.
  • Sensus Healthcare's Research & Development stood at $1.1 million in 2021, then increased by 4.7% to $1.2 million in 2022, then plummeted by 41.54% to $677000.0 in 2023, then soared by 130.58% to $1.6 million in 2024, then rose by 20.56% to $1.9 million in 2025.
  • The last three reported values for Research & Development were $1.9 million (Q4 2025), $1.8 million (Q3 2025), and $1.5 million (Q2 2025) per Business Quant data.